Form HLTH5473 Special Authority Request - Sofosbuvir in Combination With Ribavirin (Rbv) for Chronic Hepatitis C - British Columbia, Canada

Form HLTH5473 Special Authority Request - Sofosbuvir in Combination With Ribavirin (Rbv) for Chronic Hepatitis C is used in British Columbia, Canada to request special authority for the use of the medication Sofosbuvir in combination with Ribavirin for the treatment of chronic Hepatitis C.

The form HLTH5473 Special Authority Request - Sofosbuvir in Combination With Ribavirin (Rbv) for Chronic Hepatitis C in British Columbia, Canada is typically filed by healthcare providers or physicians on behalf of their patients.

FAQ

Q: What is HLTH5473?
A: HLTH5473 is a special authority request form for Sofosbuvir in combination with Ribavirin (Rbv) for the treatment of chronic Hepatitis C in British Columbia, Canada.

Q: What is Sofosbuvir?
A: Sofosbuvir is a medication used in the treatment of chronic Hepatitis C. It works by stopping the virus from multiplying.

Q: What is Ribavirin?
A: Ribavirin is another medication used in combination with Sofosbuvir for the treatment of chronic Hepatitis C. It helps to enhance the effectiveness of the treatment.

Q: Who can request Sofosbuvir in combination with Ribavirin?
A: Healthcare providers in British Columbia, Canada can request Sofosbuvir in combination with Ribavirin for patients with chronic Hepatitis C.

Q: What is the purpose of this special authority request?
A: The special authority request is required to ensure that the treatment is appropriate and necessary for the patient's condition.

Q: Is this treatment covered by the healthcare system in British Columbia?
A: Yes, if the special authority request is approved, the treatment will be covered by the healthcare system in British Columbia.

Q: Is this treatment available for all patients with chronic Hepatitis C?
A: The availability of Sofosbuvir in combination with Ribavirin depends on the patient's specific circumstances and the recommendation of their healthcare provider.